Message from the Chairman

For the past 25 years, NatureCell, together with the Biostar Group, has pursued new frontiers in treating incurable and degenerative diseases through adult stem cell technology. Despite numerous challenges—including regulatory constraints, market skepticism, and trial and error—we have remained committed to our core principles: science-based research and development, and delivering practical solutions for patients.

Since our founding, we have built strong R&D capabilities in stem cell technology. Through clinical experience in regenerative medicine in China and Japan, we have gained valuable real-world data and operational expertise. While regulatory changes presented challenges both domestically and internationally, these experiences ultimately strengthened our technology and organization.

Beginning in 2019, we reaffirmed our core values and clarified our identity as a global, research-driven biotech company. As part of this effort, we established the Biostar Stem Cell Campus in Baltimore, Maryland—marking a significant step into the U.S. market. This move represents not just geographic expansion, but a strategic commitment to validating and commercializing our technology within a global regulatory framework.

The year 2026 marks an important turning point for both Biostar Group and NatureCell. Moving forward, we are focused on several key priorities: advancing global clinical trials and regulatory strategies centered in the U.S.; achieving meaningful progress across core pipelines, including treatments for degenerative arthritis, autoimmune diseases, and severe ischemic conditions; strengthening systems across R&D, manufacturing, quality, and clinical operations to meet global standards; and reinforcing trust through transparent governance and responsible management.

Over the mid- to long-term, we aim to secure FDA approval for at least three stem cell therapies based in Maryland by 2031 and bring them to the global market. Through these efforts, we strive to expand treatment options for patients worldwide while achieving sustainable growth. Thank you. Sincerely,

NatureCell has always prioritized long-term sustainability over short-term gains. While choosing the right path over the fastest one may have seemed gradual at times, we are confident in the foundation we have built and remain committed to proving its value.

Looking ahead, NatureCell will continue to grow as a trusted global regenerative medicine leading company through science-driven innovation, accountability to our stakeholders, and operations aligned with international standards.